Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30578988 | 1.00 | BRD4 (0.39) | BRD4LMNAS1PR2PARP1HTT | |
| SCHEMBL2526042 | 0.83 | TPMT (0.43) | LMNAS1PR2TSHRSMN1; SMN2 | |
| SCHEMBL3281481 | 0.82 | LMNA (0.48) | BRD4LMNAS1PR2PARP1HTT | |
| SCHEMBL29102677 | 0.78 | TDP1 (0.37) | S1PR2 | |
| SCHEMBL1425072 | 0.78 | HTT (0.43) | BRD4LMNAPARP1HTTPOLB | |
| SCHEMBL3511223 | 0.77 | ALDH1A1 (0.48) | LMNAS1PR2HTTPOLBSMN1; SMN2 | |
| Nitrous Acid SCHEMBL29102679 | 0.77 | TPMT (0.38) | S1PR2TSHRSMN1; SMN2 | |
| SCHEMBL13280621 | 0.77 | IKBKB (0.40) | BRD4LMNAHTTTSHRSMN1; SMN2 | |
| Benzamide SCHEMBL29088364 | 0.76 | PARP1 (0.57) | BRD4PARP1MKNK1MKNK2POLB | |
| SCHEMBL27682477 | 0.76 | TSHR (0.48) | BRD4LMNAPARP1MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368147-A1 | CYCLIN K DEGRADER | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4382519-A1 | CYCLIN K DEGRADATION AGENT | Adlai Nortye Biopharma Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| CN-116848099-A | Cyclin K degrading agent | 杭州阿诺生物医药科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2023025225-A1 | CYCLIN K DEGRADATION AGENT | 杭州阿诺生物医药科技有限公司 | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368147-A1 | CYCLIN K DEGRADER | CCNK, CCNI, CDK1 | BRD4 1837/4885LMNA 929/4885S1PR2 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.